Ignite Creation Date:
2025-12-25 @ 2:15 AM
Ignite Modification Date:
2026-01-16 @ 10:39 AM
Study NCT ID:
NCT03813160
Status:
COMPLETED
Last Update Posted:
2022-08-16
First Post:
2019-01-21
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Switzerland'], 'submissionTracking': {'submissionInfos': [{'resetDate': '2023-12-04', 'mcpReleaseN': 25, 'releaseDate': '2023-11-13'}], 'estimatedResultsFirstSubmitDate': '2023-11-13'}}, 'conditionBrowseModule': {'meshes': [{'id': 'D003882', 'term': 'Dermatomyositis'}], 'ancestors': [{'id': 'D017285', 'term': 'Polymyositis'}, {'id': 'D009220', 'term': 'Myositis'}, {'id': 'D009135', 'term': 'Muscular Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D003240', 'term': 'Connective Tissue Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C471849', 'term': 'lenabasum'}, {'id': 'C000634129', 'term': 'anabasum'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2021-01-13', 'size': 4028023, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2022-04-05T17:02', 'hasProtocol': True}, {'date': '2021-05-26', 'size': 16728517, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2022-04-05T15:57', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 176}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-12-17', 'type': 'ACTUAL'}, 'statusVerifiedDate': '2022-08', 'completionDateStruct': {'date': '2021-10-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-08-15', 'studyFirstSubmitDate': '2019-01-21', 'studyFirstSubmitQcDate': '2019-01-21', 'lastUpdatePostDateStruct': {'date': '2022-08-16', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-01-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-03-31', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Efficacy of lenabasum 20 mg BID compared to placebo BID as measured by Total Improvement Score (TIS)', 'timeFrame': 'Week 28', 'description': 'TIS from IMAC Core Set Measures (CSM) will be calculated following Aggarwal et al (2017) recommendations. Scores are based on a 0 - 100 scale; higher scores indicate better improvement in myositis.'}], 'secondaryOutcomes': [{'measure': 'Subjects who achieve Definition of Improvement (DOI)', 'timeFrame': 'Week 28', 'description': 'Defined as ≥ 3 of 6 core set measures improved by ≥ 20% (relative to Baseline) with no more than 2 core set measures worsening by ≥ 25% (MMT-8 may not decrease by ≥ 25% from baseline)'}, {'measure': 'Subjects who improve by at least one category on the Investigator Global Assessment (IGA) scale of skin activity', 'timeFrame': 'Week 28', 'description': 'The IGA is used by the investigator to score overall skin disease on a 0 to 4 scale; higher scores indicate greater skin disease.'}, {'measure': 'Change in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score', 'timeFrame': 'Week 28', 'description': 'CDASI is a validated outcome measure that systematically quantifies cutaneous DM disease activity and damage (Klein et al, 2007; Yassaee et al, 2010) Disease Activity Score is rated using three activity measures. The activity score ranges from 0 to 100. Higher scores indicate greater disease severity.'}, {'measure': 'Subjects who achieve TIS >= 40 (at least moderate improvement)', 'timeFrame': 'Week 28', 'description': 'TIS from IMAC Core Set Measures (CSM) will be calculated following Aggarwal et al (2017) recommendations. Scores are based on a 0 - 100 scale; higher scores indicate better improvement in myositis.'}, {'measure': 'TIS in subjects receiving immunosuppressive therapies (including corticosteroids) for > 1 year at Baseline', 'timeFrame': 'Week 52', 'description': 'TIS from IMAC Core Set Measures (CSM) will be calculated following Aggarwal et al (2017) recommendations. Scores are based on a 0 - 100 scale; higher scores indicate better improvement in myositis.'}, {'measure': 'Change in Forced vital capacity (FVC) absolute, in all subjects and those with interstitial lung disease (ILD) at Baseline.', 'timeFrame': 'Week 28', 'description': 'ILD is defined as a history of fibrosis on chest x-ray, a history of ILD on CT of lungs, and/or FVC% predicted \\<80% at Screening or Visit 1'}, {'measure': 'Change in Forced vital capacity (FVC) percent predicted, in all subjects and those with interstitial lung disease (ILD) at Baseline.', 'timeFrame': 'Week 28', 'description': 'ILD is defined as a history of fibrosis on chest x-ray, a history of ILD on CT of lungs, and/or FVC% predicted \\<80% at Screening or Visit 1'}, {'measure': 'TIS at Visit 10', 'timeFrame': 'Week 52', 'description': 'TIS from IMAC Core Set Measures (CSM) will be calculated following Aggarwal et al (2017) recommendations. Scores are based on a 0 - 100 scale; higher scores indicate better improvement in myositis.'}, {'measure': 'TIS, lenabasum 5 mg BID versus placebo', 'timeFrame': 'Week 28', 'description': 'TIS from IMAC Core Set Measures (CSM) will be calculated following Aggarwal et al (2017) recommendations. Scores are based on a 0 - 100 scale; higher scores indicate better improvement in myositis.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['dermatomyositis', 'cannabinoid receptor type 2 agonist', 'JBT-101', 'lenabasum'], 'conditions': ['Dermatomyositis']}, 'referencesModule': {'references': [{'pmid': '40383862', 'type': 'DERIVED', 'citation': "Kodali N, Diaz D, Dhiman R, Vazquez T, Feng R, Patel J, Dan J, Sprow G, Kleitsch J, Sharma M, Bashir M, Werth VP. Diverse Lenabasum pathway activation in dermatomyositis patients' blood. Sci Rep. 2025 May 18;15(1):17232. doi: 10.1038/s41598-025-92001-z."}]}, 'descriptionModule': {'briefSummary': 'This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis. Approximately 150 subjects will be enrolled in this study at about 60 sites in North America, Europe, and Asia. The planned duration of double-blind treatment with study drug is up to 52 weeks.', 'detailedDescription': 'Subjects will be randomized to receive lenabasum 20 mg twice per day, lenabasum 5 mg twice per day, or placebo twice per day in a 2:1:2 ratio. The primary efficacy outcome at Week 28 will compare lenabasum 20 mg BID to placebo the Total Improvement Score (TIS), which is a weighted composite measure of improvement from baseline in six endpoints: Physician Global Assessment of Disease Activity, Physician Assessment of Extramuscular Disease Activity, Patient Global Assessment of Disease Activity, Health Assessment Questionnaire (patient-reported disability), Manual Muscle Testing (MMT), and muscle enzymes.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Fulfill at least one of the following criteria for dermatomyositis:\n\n 1. Bohan and Peter criteria (Bohan and Peter, 1975a; Bohan and Peter 1975b)\n 2. ACR/EULAR criteria (Lundberg et al, 2017)\n* Disease activity/severity fulfills at least one of the following three criteria:\n\n 1. MDGA ≥ 3 cm (0 - 10 cm Visual Analog Scale \\[VAS\\]) and MMT-8 score ≤ 142 (out of 150 total possible)\n 2. Sum of MDGA, PtGA and EMGA VAS scores is ≥ 10 cm (0-10 cm VAS for each)\n 3. MDGA ≥ 3 cm (0-10 cm VAS) and CDASI activity score of \\> 14\n* Stable doses of immunosuppressive medications for DM as defined by:\n\n 1. Unchanged dose of oral corticosteroids ≤ 20 mg per day prednisone or equivalent for ≥ 4 weeks before Visit 1\n 2. Unchanged dose of immunosuppressive medications other than oral corticosteroids for ≥ 8 weeks before Screening\n\nExclusion Criteria:\n\n* Unstable DM or DM with end-stage organ involvement at Screening or Visit 1\n* Significant diseases or conditions other than DM that may influence response to the study drug or safety\n* Any of the following values for laboratory tests at Screening:\n\n 1. A positive pregnancy test (or at Visit 1)\n 2. Hemoglobin \\< 9 g/dL in males and \\< 8 g/dL in females\n 3. Neutrophils \\< 1.0 × 10\\^9/L\n 4. Platelets \\< 75 × 10\\^9/L\n 5. Creatinine clearance \\< 50 mL/min on screening blood test, per the Modification of Diet in Renal Disease Study or in 24 hour urine creatine clearance measurement'}, 'identificationModule': {'nctId': 'NCT03813160', 'acronym': 'DETERMINE', 'briefTitle': 'Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Corbus Pharmaceuticals Inc.'}, 'officialTitle': 'A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis', 'orgStudyIdInfo': {'id': 'JBT101-DM-002'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Lenabasum 20 mg', 'description': 'Subjects will receive lenabasum 20 mg twice daily', 'interventionNames': ['Drug: Lenabasum 20 mg']}, {'type': 'EXPERIMENTAL', 'label': 'Lenabasum 5 mg', 'description': 'Subjects will receive lenabasum 5 mg twice daily', 'interventionNames': ['Drug: Lenabasum 5 mg']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Subjects will receive placebo twice daily', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Lenabasum 20 mg', 'type': 'DRUG', 'otherNames': ['JBT-101', 'anabasum'], 'description': 'oral capsule', 'armGroupLabels': ['Lenabasum 20 mg']}, {'name': 'Lenabasum 5 mg', 'type': 'DRUG', 'otherNames': ['JBT-101', 'anabasum'], 'description': 'oral capsule', 'armGroupLabels': ['Lenabasum 5 mg']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'oral capsule', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85018', 'city': 'Phoenix', 'state': 'Arizona', 'country': 'United States', 'facility': 'HonorHealth Neurology', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '85259', 'city': 'Scottsdale', 'state': 'Arizona', 'country': 'United States', 'facility': 'Mayo Clinic', 'geoPoint': {'lat': 33.50921, 'lon': -111.89903}}, {'zip': '90211', 'city': 'Beverly Hills', 'state': 'California', 'country': 'United States', 'facility': 'Attune Health Center', 'geoPoint': {'lat': 34.07362, 'lon': -118.40036}}, {'zip': '90095', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'UCLA Division of Rheumatology', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '80230', 'city': 'Denver', 'state': 'Colorado', 'country': 'United States', 'facility': 'Denver Arthritis Clinic', 'geoPoint': {'lat': 39.73915, 'lon': -104.9847}}, {'zip': '20001', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'country': 'United States', 'facility': 'Georgetown University', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'zip': '32224', 'city': 'Jacksonville', 'state': 'Florida', 'country': 'United States', 'facility': 'Mayo Clinic', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'zip': '33136', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'University of Miami', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33612', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'University of South Florida', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Northwestern University', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '66160', 'city': 'Kansas City', 'state': 'Kansas', 'country': 'United States', 'facility': 'University of Kansas Medical Center', 'geoPoint': {'lat': 39.11417, 'lon': -94.62746}}, {'zip': '70115', 'city': 'New Orleans', 'state': 'Louisiana', 'country': 'United States', 'facility': 'DelRicht Research', 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'zip': '21224', 'city': 'Baltimore', 'state': 'Maryland', 'country': 'United States', 'facility': 'Johns Hopkins Bayview Medical Center', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '48109', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'University of Michigan', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '55455', 'city': 'Minneapolis', 'state': 'Minnesota', 'country': 'United States', 'facility': 'University of Minnesota, Division of Rheumatic and Autoimmune Diseases', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'zip': '63110', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Washington University in St. Louis', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '10021', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Hospital for Special Surgery', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '44195', 'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'facility': 'Cleveland Clinic', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '19104', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'University of Pennsylvania', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '15261', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'University of Pittsburgh, Division of Rheumatology', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '29425', 'city': 'Charleston', 'state': 'South Carolina', 'country': 'United States', 'facility': 'MUSC: Department of Neurology', 'geoPoint': {'lat': 32.77632, 'lon': -79.93275}}, {'zip': '78756', 'city': 'Austin', 'state': 'Texas', 'country': 'United States', 'facility': 'Austin Neuromuscular Center', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'zip': '53217', 'city': 'Glendale', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'Rheumatic Disease Center', 'geoPoint': {'lat': 43.13529, 'lon': -87.93564}}, {'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'University Hospital "Kaspela" Rheumatology Clinic', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'UMHAT "St. Ivan Rilski"', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '6000', 'city': 'Stara Zagora', 'country': 'Bulgaria', 'facility': 'UMHAT', 'geoPoint': {'lat': 42.43205, 'lon': 25.64262}}, {'zip': 'V5Z 4E8', 'city': 'Vancouver', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'University of British Columbia, Dept. of Dermatology and Skin Science', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'zip': '12850', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Revmatologicky ustav', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'city': 'Berlin', 'country': 'Germany', 'facility': 'Charite-Universitatsmedizin', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': 'D- 91054', 'city': 'Erlangen', 'country': 'Germany', 'facility': 'University Hospital Erlangen Nuremberg', 'geoPoint': {'lat': 49.59099, 'lon': 11.00783}}, {'city': 'Göttingen', 'country': 'Germany', 'facility': 'University Medical Center Goettingen', 'geoPoint': {'lat': 51.53443, 'lon': 9.93228}}, {'city': 'Debrecen', 'country': 'Hungary', 'facility': 'University of Debrecen', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'zip': '95121', 'city': 'Catania', 'country': 'Italy', 'facility': 'University Hospital Policlinico-Vittorio Emanuele', 'geoPoint': {'lat': 37.49223, 'lon': 15.07041}}, {'zip': '00168', 'city': 'Roma', 'country': 'Italy', 'facility': 'Fondazione Policlinico Universitario A.Gemelli-IRCCS', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'city': 'Gunma', 'country': 'Japan', 'facility': 'Gunma University Hospital'}, {'city': 'Hokkaido', 'country': 'Japan', 'facility': 'Hokkaido University Hospital'}, {'city': 'Kanagawa', 'country': 'Japan', 'facility': 'Yokohama City University Hospital', 'geoPoint': {'lat': 37.58333, 'lon': 139.91667}}, {'city': 'Kyoto', 'country': 'Japan', 'facility': 'Kyoto University Hospital', 'geoPoint': {'lat': 35.02107, 'lon': 135.75385}}, {'city': 'Miyagi', 'country': 'Japan', 'facility': 'Tohoku University Hospital', 'geoPoint': {'lat': 26.62566, 'lon': 128.18236}}, {'city': 'Osaka', 'country': 'Japan', 'facility': 'Osaka University Hospital', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}, {'city': 'Tokyo', 'country': 'Japan', 'facility': 'Keio University Hospital', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'city': 'Tokyo', 'country': 'Japan', 'facility': 'Nippon Medical School Hospital', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'city': 'Wakayama', 'country': 'Japan', 'facility': 'Wakayama Medical Hospital', 'geoPoint': {'lat': 34.23333, 'lon': 135.16667}}, {'city': 'Bialystok', 'country': 'Poland', 'facility': 'KLIMED', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'zip': '35-055', 'city': 'Rzeszów', 'country': 'Poland', 'facility': 'Kliniczny Szpital Wojewodzki Nr 1. im Fryderyka Chopina Klinika Dermatologii', 'geoPoint': {'lat': 50.04132, 'lon': 21.99901}}, {'zip': '18-404', 'city': 'Łomża', 'country': 'Poland', 'facility': 'KLIMED', 'geoPoint': {'lat': 53.17806, 'lon': 22.05935}}, {'city': 'Incheon', 'country': 'South Korea', 'facility': 'Inha University Hospital', 'geoPoint': {'lat': 37.45646, 'lon': 126.70515}}, {'zip': '03080', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Hanyang University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': "Seoul St. Mary's Hospital", 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Barcelona', 'country': 'Spain', 'facility': "Vall d'Hebron General Hospital", 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital 12 Octubre', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Stockholm', 'country': 'Sweden', 'facility': 'Karolinska University Hospital, Rheumatology Clinic', 'geoPoint': {'lat': 59.32938, 'lon': 18.06871}}, {'city': 'London', 'country': 'United Kingdom', 'facility': "King's College Hospital NHS Foundation Trust", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}], 'overallOfficials': [{'name': 'Victoria P Werth, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Pennsylvania'}, {'name': 'Chester V Oddis, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Pittsburgh Department of Medicine/Division of Rheumatology'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Corbus Pharmaceuticals Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}